Author

D. T. Frederick

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Research Focus:differential expression· 5 Approach:statistical model· 5 Research Focus:cell type annotation· 4 Assay:scRNA-seq· 3 Research Focus:gene regulatory network inference· 2 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1

Frequent Co-Authors

G. M. Boland· 5 shared D. Liu· 3 shared K. T. Flaherty· 3 shared R. J. Sullivan· 3 shared A. Mehta· 2 shared A. Y. Huang· 2 shared J. Chen· 2 shared M. Kellis· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

G. M. Boland

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma

G. Tarantino, C. A. Ricker, A. Wang, W. Ge, T. J. Aprati, A. Y. Huang, S. Madha, J. Chen, Y. Shi, M. Glettig, D. T. Frederick, S. Freeman, M. M. Holovatska, M. P. Manos, L. Zimmer, , D. Liu

This study identifies genomic heterogeneity and ploidy as markers of intrinsic resistance to PD-1 blockade in metastatic melanoma, with a decision tree model predicting resistance with high confidence.

Science Advances · Nov 29, 2024Peer-reviewedCancer Biology

Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma

J. Yang, C. Wang, D. Fu, L.-L. Ho, K. Galani, L. Chen, D. T. Frederick, L. He, A. Y. Huang, E. J. Robitschek, S. K. Yadav, W. Deng, R. Tacke, K. P. Burke, T. Sharova, , M. Kellis

The paper identifies a mature dendritic cell subtype associated with improved immune response and prognosis in melanoma patients treated with anti-PD-1 checkpoint inhibitors.

bioRxiv · Jun 20, 2024Cancer Biology

Plasma proteomic biomarkers identify non-responders and reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockade

A. Mehta, M. Rucevic, E. Sprecher, M. Parikh, J. Chem, D. T. Frederick, E. Woods, L. Bi, D. Lieb, L. Hultin-Rosenberg, J. Guess, R. J. Park, A. Schneider, W. Michaud, B. Miao, , G. M. Boland

The paper identifies plasma proteomic biomarkers that predict non-response to PD1 blockade in melanoma patients and links them to tumor microenvironment biology.

bioRxiv · Feb 2, 2022 · PreprintCancer Biology

Microenvironmental correlates of immune checkpoint inhibitor response in human melanoma brain metastases revealed by T cell receptor and single-cell RNA sequencing

C. A. Alvarez-Breckenridge, S. C. Markson, J. H. Stocking, N. Nayyar, M. Lastrapes, M. R. Strickland, A. E. Kim, M. de Sauvage, A. Dahal, J. M. Larson, J. L. Mora, A. W. Navia, B. M. Kuter, C. M. Gill, M. S. Bertalan, , Bra

bioRxiv · Aug 25, 2021Cancer Biology

Multicellular immune hubs and their organization in MMRd and MMRp colorectal cancer

K. Pelka, M. Hofree, J. Chen, S. Sarkizova, J. D. Pirl, V. Jorgji, A. Bejnood, D. Dionne, W. H. Ge, K. H. Xu, S. X. Chao, D. R. Zollinger, D. J. Lieb, J. W. Reeves, C. A. Fuhrman, , J

The paper identifies immune hubs in colorectal cancer by analyzing transcriptional and spatial patterns in MMRd and MMRp tumors.

bioRxiv · Jan 30, 2021 · PreprintCancer Biology

Plasma-derived exosomal analysis and deconvolution enables prediction and tracking of melanoma checkpoint blockade response

A. Shi, G. G. Kasumova, W. A. Michaud, J. Cintolo-Gonzalez, J. F. Ohmura, A. Mehta, I. Chien, D. T. Frederick, S. Cohen, D. Plana, D. Johnson, K. T. Flaherty, R. J. Sullivan, M. Kellis, G. M. Boland

This paper uses plasma-derived exosomal RNA to predict and track melanoma response to immune checkpoint inhibitors by analyzing tumor and immune signatures.

bioRxiv · Oct 18, 2019 · PreprintCancer Biology